Combined lamivudine and hepatitis B immunoglobulin to prevent hepatitis B recurrence after liver transplantation:a Meta-analysis study / 第三军医大学学报

ABSTRACT

Objective To evaluate the efficiency of lamivudine combined with hepatitis B immunoglobulin to prevent hepatitis B recurrence after liver transplantation.Methods The literature concerning the application of lamivudine and hepatitis B immunoglobulin after liver transplantation was collected.The efficacy of initial lamivudine,and hepatitis B immunoglobulin alone or combined together was evaluated in liver transplantation recipients with hepatitis B by performing a systematic review of the literature with a Meta-analysis of clinical trials.Odds ratio(OR)was applied to evaluate the effect of therapeutic alliance to decrease the reinfection rate whether or not.Results We identified 7 clinical trials,and there were 360 patients subjected.OR and 95% confidence interval(95%CI)was 0.34(95%CI ranging from 0.18 to 0.64).For overall test result,Z value was 3.33 and P value was 0.01.The P value was 0.310 for our test of study homogeneity.Conclusion Our meta-analysis shows that lamivudine or hepatis B immunoglobulin can effective prevent hepatitis B recurrence after liver transplantation,and therapeutic alliance is more effective than monotherapy,and tolerance to lamivudine or hepatis B immunoglobulin was good.